Return to work for stroke survivors with aphasia: A quantitative scoping review.

The international incidence of stroke in people of working age is rising. As such, meaningful work return is a major rehabilitation goal for many individuals, including those with aphasia. This scoping review aimed to outline the post-stroke aphasia evidence related to work outcomes, factors influencing employment along with contemporary vocational-language and communication rehabilitation practice. The review employed terms related to aphasia, stroke, rehabilitation, and return to work in publications preceding 25.6.2023. Data were descriptively analysed, and vocational outcomes were summarized at defined timepoints. Of the 908 articles reviewed, 31 papers were included. Individuals with post-stroke aphasia consistently have lower rates of return to work than those post-stroke without aphasia. Employment at one year was 34.29% for those with aphasia compared to 58.46% for people without aphasia. No literature reported vocational-language assessment practices and there were minimal work-focused aphasia interventions identified. There was insufficient evidence to clearly identify person-related, rehabilitation, workplace or other factors influencing work return. This scoping review has identified that there are gaps in knowledge about the factors that influence work return and targeted vocational rehabilitation for this group. Future research to optimize return to work for individuals with aphasia is recommended.

Inmunogenicidad e inocuidad de una vacuna contra rotavirus / Immnunogenicity and innocuid by rotavirus vaccine

Las enfermedades diarreicas están difundidas y causan todos los años la muerte de más de 4,5 millones de menores de 5 años, la importancia que presentan los rotavirus como agentes virales ha originado que se desarrollen estrategias inmunoprofilácticas, siendo de ellas la utilizadas en el desarrollo de una vacuna anti-rotavirus que consisten en el uso de una cepa animal relacionada antigenicamente y que sea capaz de crecer de manera eficiente en cultivos celulares. En este estudio fueron seleccionados 54 niños con edades entre 4 y 10 meses y recibieron 2 dosis de vacunas y el placebo. Fueron tomadas muestras de heces diariamente durante el período de observación. Los resultados preliminares de este estudio demostraron que la vacuna no produce reacciones secundarias en los diferentes grupos etarios estudiados, en especial en el grupo menor de 4 meses, en el grupo de niños de 2 a 3 meses se determinó la excreción viral en un 75